Psychedelics in mental healthcare show growing interest but uneven evidence

Few developments in psychopharmacology attract as much attention among clinicians, researchers, and the public alike, as psychedelics. The psychoactive compounds psilocybin and 3,4-methylenedioxymethamphetamine (MDMA), which produce profound alterations in consciousness and mental state, have reached phase 3 trials for treatment resistant depression and post-traumatic stress disorder (PTSD) respectively. These advances reflect a resurgence of interest after decades of regulatory prohibition,1 with few trials conducted before 2017, rising to over 134 registered for psilocybin alone by 2023.2 Today, what makes these drugs fascinating is their unconventional treatment model: rather than prolonged and sometimes lifelong daily dosing, psychedelics are hypothesised to produce acute and enduring change after only one to three doses.A recent review on psychedelic medicine in TheBMJ synthesises a complex body of data on the mechanisms, clinical findings, and translational challenges, and discusses key challenges including mechanistic uncertainty, functional unblinding, inconsistent adverse event monitoring, and scalability (doi:10.1136/bmj-2024-081723).3 Although findings from…